Search
Mifamurtide
go.drugbank.com/drugs/DB13615ApprovedInvestigationalWhile about 90% of patients with newly diagnosed osteosarcoma may achieve complete remission from first-line therapies, the prognosis is still poor for patients with non-metastatic osteosarcoma with lower … In the US, it is currently under investigation that holds orphan drug status for the treatment of osteosarcoma [A31746].
Products: MEPACT 4 MG INFÜZYONLUK DISPERSIYON KONSANTRESI IÇIN TOZ ,FLAKON, 1 ADETDulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigationalIt is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.[L34665] … Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct
Categories: Drugs Used in DiabetesProducts: TRULICITY® 1.5 MG/0.5 ML, TRULICITY® 0.75 MG/0.5 MLThiosulfuric acid
go.drugbank.com/drugs/DB09499ApprovedInvestigational[A252827] Sodium thiosulfate is rapidly degraded in the stomach; therefore, it is normally administered through other routes, such as intravenous or topical. … [A252827] Sodium thiosulfate is approved for the treatment of acute cyanide poisoning[L310,L43332,A252832] and it is frequently used in conjunction with sodium nitrite (a salt form of [nitrous acid]).
Categories: Compounds used in a research, industrial, or household settingBelzutifan
go.drugbank.com/drugs/DB15463ApprovedInvestigational[L35995] The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. … [L36000] It was later approved for the treatment of locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL) in patients aged 12 years and older.[L49271]
Rubidium Rb-82
go.drugbank.com/drugs/DB09479ApprovedInvestigationalIt is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected
Siltuximab
go.drugbank.com/drugs/DB09036ApprovedInvestigationalSiltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. … It is administered as a 1 hour intravenous infusion every 3 weeks.
Products: SYLVANT 100 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN LİYOFİLİZE TOZ, 1 ADET, SYLVANT 400 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN LİYOFİLİZE TOZ, 1 ADETDelamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalMultidrug-resistant tuberculosis may also require more than 2 years of chemotherapy and second-line therapies with narrow therapeutic index [A31968]. … It is used in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) in a combination regimen.
Products: Deltyba Film-Coated Tablets 50 mg, DELTYBA 50 MG FLİM TABLET, 40 ADETGlofitamab
go.drugbank.com/drugs/DB16371ApprovedInvestigational[L45768] The most common type of non-Hodgkin lymphoma,[L45763] DLBCL is relatively sensitive to chemotherapy and generally responsive to first-line treatment regimens like CHOP ([cyclophosphamide], [doxorubicin … Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively.
Categories: Bispecific CD20-directed CD3 T Cell EngagerMaribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigational[A242557] Maribavir is novel in that it instead targets the CMV pUL97 kinase, thereby providing an effective alternative treatment option in cases of resistant infections. … Maribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation.
Products: Livtencity 200 mg Film Kaplı Tablet (28 Adet), Livtencity 200 mg Film Kaplı Tablet (56 Adet)Garadacimab
go.drugbank.com/drugs/DB15629Approved[L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan. … [L53283] It was developed by CSL Behring for use as a prophylactic agent in patients with hereditary angioedema (HAE), a rare autosomal dominant disorder that results in acute episodes of angioedema.
Categories: Drugs Used in Hereditary Angioedema